Related Experiment Video
Updated: May 13, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer
Mahmoud Tag Elsabah1, Iman Adel
1Department of Pathology, Faculty of Medicine, Misr University for Science and Technology, 6th of October City, Giza, Egypt. mahmoudtg@yahoo.com
Background:
The monoclonal antibodies (mAbs) that target the epidermal growth factor receptor (EGFR) had expanded the range of treatment options for metastatic colorectal cancer. However, such type of treatment was shown to be ineffective if there is K-ras mutation. In most previous studies K-ras gene mutation was mainly assessed by PCR.
Aim:
Our work is designed to detect K-ras protein expression by immunohistochemistry (IHC) aiming to reach a preliminary method that could be confirmed by PCR and considered an alternative way for the detection of K-ras aberration. We are also aiming to find a relation between K-ras protein expression and K-ras gene mutation.
Materials And Methods:
Paraffin embedded tissue samples from 26 metastatic colorectal cancer (mCRC) patients were analyzed for K-ras protein expression by IHC using Rap1A polyclonal antibody. Staining patterns were subjectively assessed and correlated with clinicopathological features. The results were statistically evaluated using the Chi-square test.
Results:
K-ras cytoplasmic positivity was observed in 42.3% of cases. The positivity was either strong in 26.9% or moderate in 15.4%. With respect to adenocarcinoma variants, 50% of cases were positive for K-ras protein expression while all mucinous and signet ring types were negative. The positivity was noted in 50% of moderately differentiated GII colorectal carcinomas as compared with 38.9% in poorly differentiated GIII. Positive staining was observed in 40% of cases with positive lymph node metastasis while in the absence of nodal metastasis the positivity was 45.5%. No significant correlation was found between clinicopathological parameters and K-ras staining results.
Conclusion:
IHC may compliment PCR in the detection of K-ras mutation.
Insights
Immunohistochemistry (IHC) can detect K-ras protein expression in metastatic colorectal cancer (mCRC), potentially serving as an alternative to PCR for identifying K-ras aberrations. This method may complement existing K-ras mutation detection techniques.
Area of Science:
- Oncology
- Molecular Pathology
- Cancer Diagnostics
Background:
- Monoclonal antibodies targeting EGFR are used for metastatic colorectal cancer (mCRC).
- EGFR-targeted therapies are ineffective in patients with K-ras mutations.
- K-ras gene mutation detection traditionally relies on Polymerase Chain Reaction (PCR).
Purpose of the Study:
- To evaluate immunohistochemistry (IHC) for detecting K-ras protein expression as an alternative to PCR.
- To establish a preliminary IHC method for K-ras aberration detection.
- To explore the relationship between K-ras protein expression and K-ras gene mutation.
Main Methods:
- Analyzed 26 metastatic colorectal cancer (mCRC) paraffin-embedded tissue samples.
- Assessed K-ras protein expression using IHC with Rap1A polyclonal antibody.
- Correlated IHC staining patterns with clinicopathological features and analyzed data using the Chi-square test.
Main Results:
- K-ras cytoplasmic positivity was observed in 42.3% of mCRC cases (26.9% strong, 15.4% moderate).
- Adenocarcinoma variants showed 50% K-ras positivity; mucinous and signet ring types were negative.
- No significant correlation was found between K-ras staining and clinicopathological parameters.
Conclusions:
- Immunohistochemistry (IHC) shows promise as a complementary method for K-ras mutation detection in mCRC.
- IHC may offer an alternative or supplementary approach to PCR for assessing K-ras status.
- Further validation is suggested for IHC as a reliable K-ras aberration detection tool.
